Germain N, Gerth van Wijk R, Aballéa S, Abetz-Webb L, Domdey A, et al. (2019) The Burden of Allergic Rhinitis and Impact of GRAZAX® Grass Allergy Immunotherapy Treatment on Quality of Life in Germany and The Netherlands: Results from a Qualitative Study. Int J Aller Medications 5:038.


© 2019 Germain N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

RESEARCH ARTICLE | OPEN ACCESS DOI: 10.23937/2572-3308.1510038

The Burden of Allergic Rhinitis and Impact of GRAZAX® Grass Allergy Immunotherapy Treatment on Quality of Life in Germany and The Netherlands: Results from A Qualitative Study

Germain N1*, Gerth van Wijk R2, Aballéa S1, Abetz-Webb L3, Domdey A4, Romano M4 and Toumi M5

1Creativ-Ceutical, France

2Section of Allergology, Department of Internal Medicine, Erasmus University Medical Centre, Netherlands

3Patient-Centred Outcomes Assessment Limited, Cheshire, England

4ALK Abello A/S, Denmark

5Laboratoire de Santé Publique, Faculté de Médecine, Aix-Marseille Univerrsity, France



Allergic rhinitis is a major chronic respiratory disease that affects between 10% and 30% of adults and up to 40% of children globally. The purpose of this study was to understand the impact of allergic rhinitis and subsequent GRAZAX® grass allergy immunotherapy (AIT) treatment on adults' and adolescents' quality of life.


Clinicians treating allergic rhinitis in the Netherlands and Germany recruited adults and adolescents who had received at least 3 years of GRAZAX® treatment. Telephone interviews were conducted with patients to explore their experience of allergic rhinitis and AIT. Interview transcripts were analyzed using grounded theory methods. Saturation analysis was conducted for impact-related concepts. 3 allergists were also interviewed to explore their experience of treating allergic rhinitis.


15 adults (aged 19-61) and 18 adolescents (aged 11-17) were interviewed. Clinicians and patients reported that before treatment with GRAZAX®, the most common allergic rhinitis symptoms were nose- and eye-related. Together with coping strategies, these had considerable negative impacts on patients' quality of life. Adults and adolescents reported notable improvement or disappearance of symptoms during treatment with GRAZAX®. Symptom reduction during treatment led to positive impacts on social, work/school, and physical functioning, with less need for impactful coping strategies. Some patients experienced oral side effects in the first months of AIT, though these resolved with time. Saturation of impact-related concepts was achieved.


GRAZAX® treatment considerably improved allergic rhinitis symptoms and therefore impacted on daily life for patients during and after at least 3 years of treatment. Despite long recall periods, the consistency of reports between doctors, adolescents and adults, and achieving saturation suggest the robustness of the results; a three year course of treatment with GRAZAX® positively impacts quality of life and supports the existing clinical efficacy data on GRAZAX® treatment.